Overview

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
2016-12-06
Target enrollment:
Participant gender:
Summary
This study will evaluate the long-term safety of bimatoprost 0.01% ophthalmic solution compared with bimatoprost 0.03% ophthalmic solution in patients with glaucoma or ocular hypertension.
Phase:
Phase 4
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Ophthalmic Solutions
Pharmaceutical Solutions